Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Glaukos Corporation
  6. News
  7. Summary
    GKOS   US3773221029

GLAUKOS CORPORATION

(GKOS)
  Report
Delayed Nyse  -  04:00:01 2023-01-27 pm EST
48.04 USD   -0.29%
01/11Glaukos Announces Positive Results for iDose TR Exchange Trial Highlighting Favorable Safety and Tolerability
AQ
01/10Transcript : Glaukos Corporation Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-10-2023 05:15 PM
CI
01/10Glaukos Says iDose TR Exchange Trial Shows 'Favorable' Safety, Tolerability; Shares Up After Hours
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Earnings Flash (GKOS) GLAUKOS CORPORATION Posts Q3 Revenue $71.3M

11/02/2022 | 03:24pm EST
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about GLAUKOS CORPORATION
01/11Glaukos Announces Positive Results for iDose TR Exchange Trial Highlighting Favorable S..
AQ
01/10Transcript : Glaukos Corporation Presents at 41st Annual J.P. Morgan Healthca..
CI
01/10Glaukos Says iDose TR Exchange Trial Shows 'Favorable' Safety, Tolerability; Shares Up ..
MT
01/10Glaukos : Investor Presentation January 2023
PU
01/10Glaukos Corp : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
01/10Glaukos Announces Positive Clinical Updates for Several Corneal Health Pipeline Program..
BU
01/10Glaukos Announces Positive Results for iDose TR Exchange Trial, Highlighting Favorable ..
BU
01/10Glaukos Corporation Announces Positive Results for iDose TR Exchange Trial, Highlightin..
CI
01/10Glaukos Corporation Announces Positive Clinical Updates for Several Corneal Health Pipe..
CI
2022Glaukos Announces Participation in the J.P. Morgan Healthcare Conference 2023
AQ
More news
Analyst Recommendations on GLAUKOS CORPORATION
More recommendations
Financials (USD)
Sales 2022 280 M - -
Net income 2022 -90,2 M - -
Net Debt 2022 - - -
P/E ratio 2022 -24,4x
Yield 2022 -
Capitalization 2 290 M 2 290 M -
Capi. / Sales 2022 8,19x
Capi. / Sales 2023 7,52x
Nbr of Employees 727
Free-Float 96,0%
Chart GLAUKOS CORPORATION
Duration : Period :
Glaukos Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAUKOS CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 48,04 $
Average target price 56,70 $
Spread / Average Target 18,0%
EPS Revisions
Managers and Directors
Thomas William Burns Chairman & Chief Executive Officer
Joseph E. Gilliam President & Chief Operating Officer
Alex Thurman Chief Financial Officer & Senior Vice President
Jay L. Katz Chief Medical Officer
David F. Hoffmeister Independent Director
Sector and Competitors
1st jan.Capi. (M$)
GLAUKOS CORPORATION9.98%2 290
STRYKER CORPORATION3.96%96 186
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.8.04%19 517
SMITH & NEPHEW PLC1.13%12 116
INSPIRE MEDICAL SYSTEMS, INC.0.54%7 317
ENOVIS CORPORATION17.04%3 392